Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Ekso Bionics Holdings (EKSO) over the last 11 years, with Q1 2025 value amounting to $180000.0.

  • Ekso Bionics Holdings' Asset Writedowns and Impairment rose 160000.0% to $180000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $278000.0, marking a year-over-year increase of 13166.67%. This contributed to the annual value of $171000.0 for FY2024, which is 13750.0% up from last year.
  • Ekso Bionics Holdings' Asset Writedowns and Impairment amounted to $180000.0 in Q1 2025, which was up 160000.0% from $98000.0 recorded in Q4 2024.
  • In the past 5 years, Ekso Bionics Holdings' Asset Writedowns and Impairment ranged from a high of $180000.0 in Q1 2025 and a low of -$12000.0 during Q1 2024
  • Its 5-year average for Asset Writedowns and Impairment is $33187.5, with a median of $22000.0 in 2021.
  • In the last 5 years, Ekso Bionics Holdings' Asset Writedowns and Impairment plummeted by 130000.0% in 2024 and then skyrocketed by 160000.0% in 2025.
  • Quarter analysis of 5 years shows Ekso Bionics Holdings' Asset Writedowns and Impairment stood at $27000.0 in 2021, then soared by 62.96% to $44000.0 in 2022, then rose by 6.82% to $47000.0 in 2023, then surged by 108.51% to $98000.0 in 2024, then soared by 83.67% to $180000.0 in 2025.
  • Its last three reported values are $180000.0 in Q1 2025, $98000.0 for Q4 2024, and $34000.0 during Q3 2024.